爱博诺德2025年业绩快报：营收微增5.15%，净利润下滑超三成

Core Viewpoint - Aibono Medical Technology Co., Ltd. reported a revenue of 1.483 billion yuan for the fiscal year 2025, reflecting a year-on-year growth of 5.15%, but the net profit attributable to shareholders saw a significant decline of 31.67% to 265 million yuan [1] Financial Performance - Total revenue reached 1.483 billion yuan, up 5.15% year-on-year [1] - Net profit attributable to shareholders was 265 million yuan, down 31.67% year-on-year [1] - Net profit after deducting non-recurring gains and losses was 253 million yuan, a decrease of 35.11% year-on-year [1] Business Segment Performance - Revenue from artificial lenses grew by only 1.46% year-on-year, impacted by national procurement policies, adjustments in medical insurance payments, and contraction in some medical institutions [1] - Revenue from orthokeratology lenses increased by 4.38% year-on-year, influenced by diverse myopia prevention methods and intensified market competition [1] - Revenue from contact lenses rose by 7.53% year-on-year, but faced profit declines due to price wars on e-commerce platforms [1] Asset and Equity Position - Total assets reached 3.882 billion yuan, an increase of 11.01% from the beginning of the period [1] - Equity attributable to shareholders was 2.786 billion yuan, up 15.62%, primarily due to a targeted issuance and profit accumulation during the reporting period [1] Cash Flow - Net cash flow from operating activities increased by 4.22% year-on-year, providing assurance for ongoing operations [1]